GlassScriptPhysician profile
Brianne P Lienkamp
NPI 1639422355
$121,217.51
in general payments reported to CMS, 2019-2025
21 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,557 · 2022: $830 · 2023: $25K · 2024: $65K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $18K · Food and Beverage: $6,783 · Education: $29.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,990.00 |
| Travel and Lodging | $18,027.82 |
| Food and Beverage | $6,782.73 |
| Education | $29.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $115,853.77 | 2021-2025 | Spravato, Invega Sustenna |
| Eisai INC. | $1,440.00 | 2021 | |
| Abbvie INC. | $1,129.34 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $486.01 | 2021-2025 | Ingrezza |
| Corium, LLC | $470.90 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $461.29 | 2023-2025 | Sunosi, Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.39 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $224.17 | 2025 | Cobenfy |
| Lundbeck LLC | $149.64 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $108.37 | 2023-2024 | Trintellix |
| Indivior INC. | $96.39 | 2023-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $95.42 | 2021-2022 | |
| Alkermes, INC. | $83.56 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Neuronetics, INC. | $83.38 | 2023 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $76.41 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $38.54 | 2022-2024 | Fanapt |
| Braeburn INC. | $30.35 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $26.65 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $21.83 | 2024 | |
| Tempus Ai, INC | $21.41 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $14.69 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Lienkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.